Global /United States /Healthcare /Biotechnology /SLRX

Salarius Pharmaceuticals, Inc.

SLRX

• NASDAQ: SLRX • Delayed

0.8400USD 29%

As of 15 June 2026, Salarius Pharmaceuticals, Inc. has a market cap of $5.36M USD, ranking #44216 globally and #5639 in the United States. It ranks #3917 in the Healthcare sector, and #772 in the Biotechnology industry.

Global Rank

44216

Country Rank

5639

Sector Rank

3917

Industry Rank

772

Key Stats

Market Cap

$5.36MUSD

Enterprise Value

-$659.97KUSD

EBITDA (TTM)

-$5.56MUSD

Net Income (TTM)

-$5.0MUSD

PB Ratio

0.1

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Frederick Pierce open_in_new

Employees

Website

salariuspharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
29%	29%	1.8%	-79%	-94%	29%	-97%	-100%	-100%

News

SLRX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	SLRX Salarius Pharmaceuticals Inc ISIN: US79400X5032 Shares Out.: Shares Outstanding: 6.384M¹ Shares Float: 5.998M² TV: TradingView: NASDAQ: SLRX SA: Stock Analysis: NASDAQ: SLRX YF: Yahoo Finance: SLRX GF: Google Finance: NASDAQ: SLRX NQ: NASDAQ: SLRX BA: Barron's: SLRX MS: Morningstar: XNAS: SLRX	0.8400 USD	TV: TradingView: NASDAQ: SLRX SA: Stock Analysis: NASDAQ: SLRX YF: Yahoo Finance: SLRX GF: Google Finance: NASDAQ: SLRX NQ: NASDAQ: SLRX BA: Barron's: SLRX MS: Morningstar: XNAS: SLRX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 3M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 3M%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 515K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 490K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 467K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 338K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 892K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 836K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 790K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 789K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 524K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 479K%	-	Germany

chevron_leftBack